



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

May 27, 2025

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting held on May 27, 2025

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Tuesday, May 27, 2025, inter-alia considered and approved the following:

1. Audited Financial Results:

The Audited Financial Results for the Quarter and year ended March 31, 2025. A copy of the same is enclosed along with the Report of the Statutory Auditors thereon and a declaration signed by the Chief Financial Officer stating that the said report is with unmodified opinion.

2. Dividend:

Recommendation of Final Dividend of Re. 1.00 (Rupee 1.00) per equity share i.e. 50% on the face value of Rs. 2/- each, subject to approval of shareholders at the ensuing Annual General Meeting.

3. Appointment of Secretarial Auditors:

Based on recommendation of the Audit Committee, have approved the appointment of M/s. DSM & Associates, Practicing Company Secretaries as Secretarial Auditors of the Company for the period of five consecutive years commencing from FY 2025-26 to FY 2029-30, subject to approval of shareholders at the ensuing Annual General Meeting. Brief details of the aforesaid appointment are attached herewith in Annexure

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

The Meeting of the Board of Directors of the Company commenced at 03:30 p.m. and concluded at 04.10 p.m.

Kindly take the above information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Prachi Sathe

Company Secretary & Compliance Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



Annexure

Brief disclosures under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for appointment of M/s. DSM & Associates, as Secretarial Auditors of the Company are provided below:

Name of the Secretarial Auditor	M/s. DSM & Associates, Practicing Company Secretaries
Reason for Change viz. Appointment, reappointment, resignation, removal, death or otherwise;	Appointment of M/s. DSM & Associates, Peer Reviewed Firm of Company Secretary, (CP No.: 9511), as the Secretarial Auditor of the Company.
Date of Appointment/reappointment /cessation (as applicable) /reappointment/ Term of appointment	For a period of 5 (five) consecutive years commencing from FY 2025-26 up to FY 2029-30.
Brief Profile (in case of appointment)	<p>M/s. DSM Associates, Company Secretaries, is an embryonic firm of Practicing Company Secretaries, having diverse experience in Corporate Law matters.</p> <p>The firm is Peer Reviewed by ICSI which provides assurance of timely compliance, and advisory services for its various clients.</p> <p>The firm provides services to various Companies ensuring due compliance with respect to their duties as Corporate Compliance Consultants.</p>
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

**INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF STANDALONE
FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF SUPRIYA LIFESCIENCE LIMITED

Opinion

We have audited the accompanying Statement of Standalone Financial Results of **SUPRIYA LIFESCIENCE LIMITED** ("the Company"), for the three months and year ended March 31, 2025 ("the Statement"/"Standalone Financial Results"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financials statement:

- a. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2025.


Basis for Opinion

We conducted our audit of these Standalone Financial Results in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,

Mumbai - 400 053. Email: mumbai.kakaria@gmail.com

Website: www.kakariaassociates.com



provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited Interim Condensed Standalone Financial Statements for the three months and year ended March 31, 2025. The Company's Board of Directors are responsible for the preparation and presentation of the Standalone Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in the Ind AS 34 prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601



CA. Ujwal K. Kakaria
Partner
Membership No. – 035416
Place: - Mumbai
Date: - 27th May 2025
UDIN: - 25035416BMKTOT1031

**SUPRIYA LIFESCIENCE LIMITED**

CIN No: L51900MH2008PLC180452


207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

Part I - Statement of Standalone Audited Financial Results for the Quarter and year ended 31st March, 2025

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
		Audited	Unaudited	Audited	Audited	Audited
	Income					
I	Revenue from Operations	1,841.09	1,856.48	1,581.80	6,964.85	5,703.40
II	Other Income	29.75	20.98	21.85	98.15	106.35
III	Total Income	1,870.84	1,877.45	1,603.66	7,063.00	5,809.75
2	Expenses					
	a) Cost of Materials Consumed	1,015.31	135.97	483.56	2,324.36	1,914.30
	b) Purchase of Stock in Trade	-	-	-	-	-
	c) Change in inventories of finished goods, work in progress & stock in trade.	-467.05	481.82	99.05	(212.59)	303.11
	d. Employee benefit expenses	209.77	197.72	171.44	805.19	676.38
	e. Finance Cost	4.17	5.07	6.01	16.86	21.10
	f. Depreciation & amortisation expense	60.81	49.64	39.14	204.44	158.11
	g. Other expenditure	407.21	381.44	272.71	1,439.93	1,079.86
IV	Total Expenses	1,230.22	1,251.65	1,071.90	4,578.19	4,152.85
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	640.61	625.80	531.75	2,484.80	1,656.90
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	640.61	625.80	531.75	2,484.80	1,656.90
VIII	Tax Expense					
	a) Current Tax	127.72	137.72	89.44	566.57	371.00
	b) Deferred Tax	9.08	20.25	72.99	38.66	94.76
IX	Profit/(Loss) for the period from Continuing Operations (VII-VII)	503.82	467.83	369.32	1,879.58	1,191.14
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	503.82	467.83	369.32	1,879.58	1,191.14
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	1.16	0.81	0.45	(1.67)	21.69
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-0.29	(0.20)	(0.11)	0.42	(5.46)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	504.69	468.45	369.66	1,878.33	1,207.37
XVI	Earnings per equity Share (for continuing operation):					
	(1) Basic (In ₹)	6.29	5.82	4.59	23.35	14.80
	(2) Diluted (In ₹)	6.29	5.82	4.59	23.35	14.80
XVII	Earnings per equity Share (for discontinued operation):					
	(1) Basic (In ₹)	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):					
	(1) Basic (In ₹)	6.29	5.82	4.59	23.35	14.80
	(2) Diluted (In ₹)	6.29	5.82	4.59	23.35	14.80





See accompanying notes to the financial statements:


Notes:-

1. The audited Standalone financial results of the Company for the quarter and year ended March 31, 2025 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
2. The above audited standalone financial results of the Company for the quarter year ended March 31, 2025 have been reviewed by the Audit Committee on May 27, 2025 and thereafter approved by the Board of Directors at their meeting held on May 27, 2025.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The board of director at their meeting dated 27th May 2025 have recommended final dividend of INR 1/- Per equity share of INR 2/- each.
5. The company does not have any subsidiary/associate/joint venture company as on March 31, 2025.
6. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

Place :- Mumbai
Date :- May 27, 2025

For Supriya Lifescience Limited


Dr. Satish Waman Wagh
Chairman and Whole time director
DIN: 01456982



Supriya Lifescience Ltd

CIN No: L51900MH2008PLC180452

Standalone Balance Sheet as at March 31, 2025

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	March 31, 2025	March 31, 2024
ASSETS		
Non-current assets		
(i) Property, plant and equipment	4,468.32	3,036.97
(ii) Right to Use Asset	46.45	47.79
(iii) Capital Work in progress	1,480.15	1,488.25
(iv) Intangible Assets	13.89	16.56
(v) Financial Assets		
-Investments	632.41	637.95
-Loans and Advances	-	-
(vi) Other Non- Current Assets	111.54	6.81
Total Non-current assets	6,752.76	5,234.33
Current assets		
(i) Inventories	1,183.49	852.49
(ii) Financial Assets		
-Loans and Advances	9.27	8.97
-Trade receivables	1,343.62	1,116.83
-Cash and cash equivalents	760.57	683.49
-Bank balances other than (iii) above	30.97	66.07
-Other Financial Assets	7.11	45.09
(iii) Other current assets	1,035.35	1,207.22
Total Current Assets	4,370.38	3,980.15
TOTAL ASSETS	11,123.14	9,214.48
EQUITY AND LIABILITIES		
EQUITY		
(i) Equity share capital	160.97	160.97
(ii) Other equity	9,806.63	7,992.70
Total Equity	9,967.60	8,153.67
LIABILITIES		
Non-current liabilities		
(i) Financial Liabilities		
-Borrowings	-	-
-Lease Liabilities	50.57	50.20
-Other financial liabilities	-	-
(ii) Provisions	13.18	8.04
(iii) Deferred tax Liabilities	270.18	231.52
Total Non-Current Liabilities	333.93	289.76
Current liabilities		
(i) Financial liabilities		
-Borrowings	-	-
-Lease Liabilities	3.23	4.68
-Trade payables	-	-
Micro Enterprises and Small Enterprises		
Other than micro and small enterprises	745.46	595.69
-Other financial liabilities	17.59	15.74
(ii) Provisions	11.93	3.65
(iii) Other current liabilities	43.41	151.30
Total Current Liabilities	821.62	771.07
TOTAL EQUITY AND LIABILITIES	11,123.14	9,214.48

[Handwritten signature]




Supriya Lifescience Ltd

CIN No: L51900MH2008PLC180452

Cash flow statement for the period ended March 31, 2025

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	March 31, 2025	March 31, 2024
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	2,484.80	1,656.90
Adjustments for		
Depreciation and Amortization	204.44	158.11
Interest Income (Net of Expenses)	-78.85	-100.24
Dividend Received	-0.05	-0.05
Employee Benefit	11.75	-33.73
Loss on Sale of fixed Assets	0.06	-
Modification of Lease	-	-0.05
Operating profit before working capital changes	2,622.15	1,680.94
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	-226.79	-270.19
Inventories	-331.00	305.21
Other Non Current & Current Assets	67.15	-205.01
Other Non Current & Current Financial Assets	37.97	18.97
Loans and Advances	-0.30	-1.36
	-452.97	-152.38
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	149.76	-46.59
Other Non Current & Current Financial Liabilities	1.85	7.53
Other Non Current & Current liabilities	-82.25	20.02
	69.36	-19.04
(Income tax paid)/net of refund	-591.79	-376.45
Net Cash generated from Operating Activities	1,646.75	1,133.07
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-1,623.76	-1,456.55
(Purchase)/ Sale of Investments	5.56	-385.00
Interest Income	95.71	105.75
Dividend Received	0.05	0.05
Net Cash generated/(outflow) from Investing Activities	-1,522.44	-1,735.74
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Shares	-	-
Increase/(Decrease) in Long term borrowings	-	-
Increase/(Decrease) in Short term borrowing	-	-166.25
Finance Cost	-16.86	-5.51
Dividend Paid	-64.39	-48.29
Repayment of Lease liability	-1.08	-3.54
Net Cash generated from Financing Activities	-82.33	-223.59
Net Increase/(Decrease) in Cash and Cash equivalents	41.98	-826.25
Cash and Cash Equivalents at the end of previous period	749.56	1,575.82
Cash and Cash Equivalents as at the end of the reporting period	791.54	749.56






SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

May 27, 2025

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir (s),

Sub: Declaration pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In terms of the provisions of Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we confirm that the Statutory Auditors of the Company, M/s. Kakaria & Associates LLP, Chartered Accountants (FRN: 104558W/W100601) have issued an Audit Report with unmodified opinion in respect of Audited Financial Results of the Company for the year ended March 31, 2025 as approved by the Board at its meeting held today i.e. May 27, 2025..

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Krishna Raghunathan
Chief Financial Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE